Sunscreen Data Guidance Risk/Benefit Balance Uneven – Comments
This article was originally published in The Tan Sheet
Executive Summary
FDA's suggestion of maximal use trials to assess the systemic absorption potential for proposed sunscreen ingredients will delay consumer access to new broad-spectrum sunscreens without a sound scientific basis, say PASS, the American Cancer Society and American Academy of Dermatology Association.
You may also be interested in...
FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review
The agency maintains maximal usage trials are essential in sunscreen ingredient GRASE assessments, despite industry objections that the tests have not been used for UV filters and no protocol is established. FDA’s final guidance closely mirrors its draft issued a year ago, which stakeholders projected would further delay consumer access to updated sunscreen products.
FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review
The agency maintains maximal usage trials are essential in sunscreen ingredient GRASE assessments, despite industry objections that the tests have not been used for UV filters and no protocol is established. FDA’s final guidance closely mirrors its draft issued a year ago, which stakeholders projected would further delay consumer access to updated sunscreen products.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.